SAN DIEGO, Calif. — The U.S. Food and Drug Administration approved a label update for the 1 mg dose of neffy, an epinephrine nasal spray used in allergic emergencies, removing the minimum age requirement and expanding use based on weight, according to GlobeNewswire, BioSpace, Conexiant, Benzinga, MarketScreener, and SnackSafely. Each of the bullet points immediately below have been confirmed by at least four of the six respected sources we selected on this story.
- The FDA approved an update to the prescribing information for neffy 1 mg (epinephrine nasal spray) that removes the minimum age requirement for use.
- neffy is indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in adults and children who weigh at least 33 pounds.
- Before the update, use of the 1 mg dose for younger pediatric patients required both a weight threshold and a minimum age of 4 years; the age criterion is removed.
- The updated labeling recommends carrying neffy in its blister packaging or a dedicated carrying case, and ARS Pharmaceuticals said it will include a case with each prescription beginning this summer.
- The label update adds guidance on administration and storage, including sniffing after dosing, freeze-and-thaw handling, and tolerance for short high-temperature excursions.
- neffy is sold in two dose strengths, with 1 mg and 2 mg options tied to patient weight ranges.
Additional Details Reported
Epinephrine is the standard emergency treatment for anaphylaxis, and the updated labeling is aimed at making dose selection simpler for caregivers by relying on weight rather than age for the 1 mg product.
The revised instructions also emphasize preparedness: patients are advised to keep two devices available and to seek emergency medical care after use when additional treatment is needed.
How we report: We select the day’s most important stories, confirm key facts across multiple reputable sources, and avoid anonymous sourcing. Our goal is clear, balanced coverage you can trust.
Image Attribution ▾
Featured image: AI-generated editorial illustration via Hedra (hedra.com). Soft, clean clinical watercolor style showing a caregiver holding an unbranded nasal spray device beside a young child in a bright clinic setting, conveying allergy emergency preparedness. (Artificial Intelligence generated image / Hedra.com and EOBS.biz)
How we report: We select the day’s most important stories, confirm facts across multiple reputable sources, and avoid anonymous sourcing. Our goal is clear, balanced coverage you can trust—because transparency and verification matter for informed readers.